RT Journal Article
SR Electronic
T1 HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: A pragmatic randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.28.22276756
DO 10.1101/2022.06.28.22276756
A1 Aasbø, Gunvor
A1 Tropè, Ameli
A1 Nygård, Mari
A1 Christiansen, Irene Kraus
A1 Baasland, Ingrid
A1 Iversen, Grete Alrek
A1 Munk, Ane Cecilie
A1 Christiansen, Marit Halonen
A1 Presthus, Gro Kummeneje
A1 Undem, Karina
A1 Bjørge, Tone
A1 Castle, Philip E.
A1 Hansen, Bo Terning
YR 2022
UL http://medrxiv.org/content/early/2022/06/28/2022.06.28.22276756.abstract
AB Background The main aim of the present study is to assess whether human papillomavirus (HPV) self-sampling may increase cervical cancer screening participation among long-term non-attenders in Norway.Methods A pragmatic randomized controlled trial was initiated in the national cervical screening programme in March 2019. A random sample of 6000 women aged 35-69 years who had not attended screening for at least 10 years were randomized 1:1:1 to receive either (i) a reminder to attend regular screening (control arm), (ii) an offer to order a self-sampling kit (opt-in arm), or (iii) a self-sampling kit unsolicited (opt-out arm).Results Total screening participation during 6 months following study invitation was 4.8%, 17.0% and 27.7% among women who received a standard reminder letter (controls), women who could order a self-sample kit (opt-in) and women who received a self-sample kit unsolicited (opt-out), respectively (P<0.0001). High-risk HPV was detected in 11.5% of the self-samples and in 9.2% of the clinician-collected samples (P = 0.40). Most women (92.5%) who returned a positive self-sample attended triage. Of 933 women screened in the study (by a clinician or HPV self-sampling), 33 (3.5%) had CIN2+, 31 (3.3%) had CIN3+, and 11 (1.2%) had cervical cancer.Conclusion We conclude that opt-in and opt-out self-sampling increased screening participation among long-term non-attenders.Clinical Trial Registration ClinicalTrials.gov NCT03873376Competing Interest StatementDr. Castle has received HPV tests and assays for research at a reduced or no cost from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. All other authors declare no conflict of interest.Clinical TrialNCT03873376Funding StatementThis study was funded by the Norwegian Cancer Society and Thea Steen Memorial fund (grant number 182687-2016). The funding source had no role in study design, data collection and analysis, preparation of the manuscript, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The South-Eastern Committee A for Medical and Health Research Ethics in Norway approved the study (project-ID: 2019/111) and Oslo University Hospital Data Protection Officer approved the processing of data in the study (project-ID: 18/14056). In addition, a statement regarding the processing of personal data was also obtained from the Data Protection Officer at Akershus University Hospital. For women in self-sampling arms, the invitation included information that by returning the self-sample, they consented to the subsequent procedures described in the invitation letter. All invited women, including those in the control arm, were informed that they could withdraw from the study at any time. The study was performed in accordance with the Declaration of HelsinkiI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data contains personal information and the study participants have not consented to public data sharing. Data access requires permission by relevant Norwegian authorities.